Penn State Hershey Cancer Institute, Hershey, PA.
Harvard Medical School, Boston, MA.
Chest. 2013 May;143(5):1365-1377. doi: 10.1378/chest.12-0710.
An increasing proportion of patients with stage I non-small cell lung cancer (NSCLC) is undergoing sublobar resection (L-). However, there is little information about the risks and correlates of local recurrence (LR) after such surgery, especially compared with patients undergoing lobectomy (L+).
Ninety-three and 318 consecutive patients with stage I NSCLC underwent L- and L+, respectively, from 2000 to 2006. Median follow-up was 34 months.
In the L- group, the LR rates at 2, 3, and 5 years were 13%, 24%, and 40%, respectively. The risk of LR was significantly associated with tumor grade, tumor size, and T stage. The crude risk of LR was 33.8% (21 of 62) for patients whose tumors were grade ≥ 2. In the L+ group, the LR rates at 2, 3, and 5 years were 14%, 19%, and 24%, respectively. The risk of LR significantly increased with increasing tumor size, length of hospital stay, and the presence of diabetes. The L- group experienced a significant increase in failure in the bronchial stump/staple line compared with the L+ group (10% vs 3%; P = .04) and nonsignificant trends toward increased ipsilateral hilar and subcarinal failure rates.
Patients with stage I NSCLC who undergo L- have an increased risk of LR compared with patients undergoing L+, particularly when they have tumors grade ≥ 2 or tumor size > 2 cm. If L- is considered, additional local therapy should be considered to reduce this risk of LR, especially with tumors grade ≥ 2 or size > 2 cm.
越来越多的Ⅰ期非小细胞肺癌(NSCLC)患者接受亚肺叶切除术(L-)。然而,关于此类手术后局部复发(LR)的风险和相关因素的信息很少,尤其是与接受肺叶切除术(L+)的患者相比。
2000 年至 2006 年,93 例和 318 例连续的Ⅰ期 NSCLC 患者分别接受了 L-和 L+手术。中位随访时间为 34 个月。
在 L-组中,2、3 和 5 年的 LR 率分别为 13%、24%和 40%。LR 的风险与肿瘤分级、肿瘤大小和 T 分期显著相关。肿瘤分级≥2 的患者 LR 的粗风险为 33.8%(21/62)。在 L+组中,2、3 和 5 年的 LR 率分别为 14%、19%和 24%。LR 的风险随着肿瘤大小、住院时间和糖尿病的增加而显著增加。与 L+组相比,L-组支气管残端/吻合口失败的发生率显著增加(10%对 3%;P=0.04),同侧肺门和隆突下失败率呈增加趋势,但无统计学意义。
与接受 L+手术的患者相比,接受 L-手术的Ⅰ期 NSCLC 患者 LR 的风险增加,尤其是肿瘤分级≥2 或肿瘤大小>2cm 的患者。如果考虑行 L-手术,应考虑额外的局部治疗以降低 LR 的风险,尤其是肿瘤分级≥2 或大小>2cm 的患者。